在患有癌症和血小板缩的患者中使用抗凝剂治疗
Sebastian Szmit1,2, Jarosław Kępski3, Ewa Lech-Marańda4
1Department of Cardio-Oncology, Chair of Hematology and Transfusion Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland. s.szmit@gmail.com.
血小板数量较低的癌症患者 (血小板缺血) 面临出血风险增加,但无法预防血栓 (血栓栓塞). 静脉血栓塞栓症 (VTE) 的治疗策略必须在这些患者中平衡凝块预防与出血风险.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 心脏病学 心脏病学
背景情况:
- 癌症及其治疗通常会导致血栓栓塞并发症和血栓塞缩症.
- 血栓缩会增加出血风险,但不会预防血栓栓塞.
- 有效的抗凝药对于静脉血栓栓塞 (VTE) 的预后至关重要.
研究的目的:
- 审查临床显著血小板缺血 (血小板数 < 50 × 10 ^ 9 / L) 的癌症患者的静脉瘤治疗策略.
- 评估血小板衰竭的严重程度和持续时间对抗凝血药物选择的影响.
- 考虑血栓形成的风险,包括肺栓塞死亡率和静脉瘤复发.
主要方法:
- 文献综述侧重于VTE管理在血栓细胞缩癌症患者.
- 考虑血小板计数低于50 × 10 ^ 9 / L的治疗选择的分析.
- 讨论策略:通过血小板输血进行全方位抗凝治疗,剂量修改或中断抗凝治疗.
主要成果:
- 血栓缩症通过增加出血风险使静脉瘤管理复杂化.
- 抗凝血策略必须根据血小板计数,持续时间和血栓形成风险进行个性化.
- 治疗决策涉及平衡抗凝药疗效与出血风险.
结论:
- 在患有显著血小板缺血的癌症患者中,治疗静脉动脉瘤需要仔细考虑出血与凝血风险.
- 个性化抗凝策略对于优化患者的治疗结果至关重要.
- 可能需要进一步的研究来完善这种复杂的患者群体的治疗方案.
更多相关视频
07:08Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
Published on: September 5, 2017
04:48Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
相关概念视频
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
